Ecor1 Capital, Llc Buys 65,184 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc acquired 65,184 shares of the company’s stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $12.92 per share, with a total value of $842,177.28. Following the completion of the purchase, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock. The shares were bought at an average cost of $12.95 per share, with a total value of $86,065.70.

AnaptysBio Stock Performance

Shares of AnaptysBio stock traded up $0.12 during trading on Thursday, hitting $13.36. 465,990 shares of the company’s stock were exchanged, compared to its average volume of 390,740. AnaptysBio, Inc. has a 52-week low of $12.51 and a 52-week high of $41.31. The stock has a market capitalization of $406.53 million, a price-to-earnings ratio of -2.20 and a beta of -0.11. The business has a 50-day simple moving average of $20.47 and a 200-day simple moving average of $28.60.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, equities analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. increased its holdings in AnaptysBio by 140.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after purchasing an additional 1,265,891 shares during the last quarter. FMR LLC lifted its holdings in AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after buying an additional 438,557 shares during the last quarter. Jennison Associates LLC acquired a new stake in AnaptysBio during the third quarter worth approximately $8,874,000. Victory Capital Management Inc. increased its holdings in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after acquiring an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ANAB shares. JPMorgan Chase & Co. decreased their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial decreased their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Guggenheim dropped their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Finally, Wells Fargo & Company lowered their target price on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.